How much funding has Inmagene Biopharmaceuticals raised?

Inmagene Biopharmaceuticals has raised $121.0M in total funding, most recently a Series C round.

Who are Inmagene Biopharmaceuticals's investors?

Inmagene Biopharmaceuticals's investors include HighLight Capital, Vertex Ventures China, Deep Track Capital, Foresite Capital, Panacea Venture, KUNLUN.

What industry is Inmagene Biopharmaceuticals in?

Inmagene Biopharmaceuticals operates in Biotech, Healthcare.

Inmagene Biopharmaceuticals

Merged

Designed to be different: Developing a potential best-in-class anti-OX40 treatment with features that matter to patients | Imagene

Biotech

Healthcare

Business Model: B2B
Website: inmagenebio.com
Total Funding: $121.0M

Last Round: $100.0M Series CMay 2021
Rounds: 2

About

Inmagene Biopharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapeutics for immunological, autoimmune, and inflammatory diseases. The company's lead program was an anti-OX40 monoclonal antibody targeting immune pathways implicated in conditions such as atopic dermatitis and alopecia areata. In July 2025, Inmagene completed its merger with Ikena Oncology, with the combined entity subsequently rebranded and operating as ImageneBio, Inc.

Summary

Inmagene Biopharmaceuticals is a Biotech company. It has raised $121.0M in total across 2 rounds, most recently a $100.0M Series C round in May 2021. Investors include HighLight Capital, Vertex Ventures China and Deep Track Capital.

LinkedIn X (Twitter)